These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 20106550)

  • 1. Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease.
    Armentero MT; Sinforiani E; Ghezzi C; Bazzini E; Levandis G; Ambrosi G; Zangaglia R; Pacchetti C; Cereda C; Cova E; Basso E; Celi D; Martignoni E; Nappi G; Blandini F
    Neurobiol Aging; 2011 Dec; 32(12):2142-51. PubMed ID: 20106550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral expression of MAPK pathways in Alzheimer's and Parkinson's diseases.
    Wang S; Zhang C; Sheng X; Zhang X; Wang B; Zhang G
    J Clin Neurosci; 2014 May; 21(5):810-4. PubMed ID: 24405770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of protein kinase B in Alzheimer's neurofibrillary pathology.
    Pei JJ; Khatoon S; An WL; Nordlinder M; Tanaka T; Braak H; Tsujio I; Takeda M; Alafuzoff I; Winblad B; Cowburn RF; Grundke-Iqbal I; Iqbal K
    Acta Neuropathol; 2003 Apr; 105(4):381-92. PubMed ID: 12624792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease.
    Castri P; Iacovelli L; De Blasi A; Giubilei F; Moretti A; Tari Capone F; Nicoletti F; Orzi F
    Eur J Neurosci; 2007 Nov; 26(9):2469-72. PubMed ID: 17986027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
    Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
    Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
    Hye A; Kerr F; Archer N; Foy C; Poppe M; Brown R; Hamilton G; Powell J; Anderton B; Lovestone S
    Neurosci Lett; 2005 Jan; 373(1):1-4. PubMed ID: 15555766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.
    Harrington CR; Louwagie J; Rossau R; Vanmechelen E; Perry RH; Perry EK; Xuereb JH; Roth M; Wischik CM
    Am J Pathol; 1994 Dec; 145(6):1472-84. PubMed ID: 7992850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease.
    Ho L; Qin W; Pompl PN; Xiang Z; Wang J; Zhao Z; Peng Y; Cambareri G; Rocher A; Mobbs CV; Hof PR; Pasinetti GM
    FASEB J; 2004 May; 18(7):902-4. PubMed ID: 15033922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.
    Compta Y; Martí MJ; Ibarretxe-Bilbao N; Junqué C; Valldeoriola F; Muñoz E; Ezquerra M; Ríos J; Tolosa E
    Mov Disord; 2009 Nov; 24(15):2203-10. PubMed ID: 19795497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease.
    Blandini F; Sinforiani E; Pacchetti C; Samuele A; Bazzini E; Zangaglia R; Nappi G; Martignoni E
    Neurology; 2006 Feb; 66(4):529-34. PubMed ID: 16505307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
    Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
    J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease.
    Russ C; Lovestone S; Powell JF
    Mol Psychiatry; 2001 May; 6(3):320-4. PubMed ID: 11326302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease].
    Kaiser E; Schönknecht P; Hunt A; Thomann PA; Pantel J; Schröder J
    Z Gerontol Geriatr; 2008 Dec; 41(6):497-501. PubMed ID: 18327693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau phosphorylation and aggregation in Alzheimer's disease pathology.
    Avila J
    FEBS Lett; 2006 May; 580(12):2922-7. PubMed ID: 16529745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.